NCT06466226

Brief Summary

Patients at risk of significant intraoperative blood loss and/or potential hemodynamic instability often necessitate the placement of two or more central venous catheters, including large bore catheters. In tertiary hospitals, anesthesiologists frequently encounter patients undergoing major surgeries such as liver transplantation, lung transplantation, cardiac surgery, and vascular surgery, who require multiple central venous punctures as part of routine anesthetic management. However, most review and consensus articles do not directly address the utilization of multiple catheters in the same venous site, nor establish formal recommendations regarding this practice. The latest consensus on central venous access from the American Association of Anesthesiologists (ASA), published in 2012, briefly touches upon some aspects related to this practice but does not outline any contraindications. Thus, the investigators have identified a gap in evidence and robust prospective studies addressing the use of more than one catheter in the same site for central venous access. This lacuna underscores the importance of conducting a controlled clinical study in our institutions to establish the efficacy and safety of this approach in the perioperative context. The present study aims to evaluate the incidence of mechanical complications (such as dysrhythmias, arterial puncture, hematoma, pneumothorax/hemothorax, insertion failure, or inadequate positioning) within the first 24 hours after double puncture of the internal jugular vein compared to puncture of two distinct central vessels, in patients undergoing multiple central venous accesses during major surgeries. This study will be designed as a prospective, randomized, non-inferiority, open, parallel clinical trial with two groups for patient allocation. Patients identified for multiple central venous accesses as part of preoperative anesthetic planning will be randomly allocated to either receive two central venous accesses in two separate sites (Group I or control group) or two concurrent central venous accesses in a single internal jugular vein (Group II or intervention group). Only adult patients classified as ASA I to IV (over 18 years old), scheduled for major surgery, will be eligible for inclusion.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
156

participants targeted

Target at P75+ for not_applicable

Timeline
20mo left

Started Jul 2024

Longer than P75 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress53%
Jul 2024Dec 2027

First Submitted

Initial submission to the registry

May 17, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 20, 2024

Completed
11 days until next milestone

Study Start

First participant enrolled

July 1, 2024

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 20, 2024

Status Verified

June 1, 2024

Enrollment Period

3.3 years

First QC Date

May 17, 2024

Last Update Submit

June 17, 2024

Conditions

Keywords

central venous accesscomplicationsmajor surgery

Outcome Measures

Primary Outcomes (1)

  • Incidence of composite mechanical complications

    The main outcome is to evaluate the incidence of mechanical complications (dysrhythmias, arterial puncture, hematoma, pneumothorax/hemothorax, insertion failure or inadequate positioning) in the first 24 hours after double puncture of the internal jugular vein compared to puncture of two distinct central vessels, in patients undergoing more than one central venous access in major surgeries.

    Intraoperative

Secondary Outcomes (5)

  • Incidence of catheter-related infection

    Up to 30 days after surgery

  • Incidence of central venous catheter malfunction

    Up to 30 days after surgery

  • Insertion time of a central venous catheter

    Intraoperative (during central venous line insertion)

  • Number of attempts to pass each catheter

    Intraoperative (during central venous line insertion)

  • Incidence of venous thrombosis within 30 days

    Up to 30 days after surgery

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Multiple central venous lines in two sites separately

Procedure: Multiple central venous lines in two sites separately

Group 2

EXPERIMENTAL

Multiple central venous lines in a single internal jugular vein

Procedure: Multiple central venous lines in one site (internal jugular vein)

Interventions

Patients with two central venous lines in two sites separately (two central venous sites).

Group 1

Patients with two concomitant central venous lines in a single internal jugular vein (one central venous site).

Group 2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with preanesthetic planning for insertion of at least two central venous catheters.
  • Adult ASA I to IV patients (over 18 years old), scheduled to undergo cardiac surgeries, vascular surgeries, major abdominal or thoracic surgeries, liver transplants and lung transplants.

You may not qualify if:

  • Patients with a previous history of central venous thrombosis or central venous stenosis will be excluded from the research protocol.
  • Patients without preanesthetic planning insertion of at least two central venous catheters.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Andre P Schmidt, MD

    Hospital Nossa Senhora da Conceição

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andre P Schmidt, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
No masking is possible considering the intervention.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 17, 2024

First Posted

June 20, 2024

Study Start

July 1, 2024

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

December 31, 2027

Last Updated

June 20, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share